Combination of car t-cell therapy with btk inhibitors and methods of use thereof
AssigneeViracta Therapeutics, Inc.
InventorsJudith A. FOX, Pietro TAVERNA
Life of this patent
Estimating the term…
Abstract
The present disclosure provides the use of immune effector cells (e.g., T-cells or NK cells) engineered to express a Chimeric Antigen Receptor (CAR), in combination with a kinase inhibitor (e.g., a BTK inhibitor), for the treatment of a disease or disorder (e.g., a hematological malignancies).
Claims50
Use of immune effector cells engineered to express a Chimeric Antigen Receptor (CAR), in combination with a kinase inhibitor, for the treatment of a disease or disorder in a subject in need thereof.
A combination comprising:
- a. immune effector cells engineered to express a Chimeric Antigen Receptor (CAR);
- and
- b. a BTK inhibitor.
A method for treating or delaying progression of a cancer in a subject comprising administering to the subject a therapeutically effective amount of a reversible BTK inhibitor, wherein the subject is receiving or has received a CART cell therapy that specifically targets an antigen associated with or expressed by a plurality of cancer cells.
A method of inducing or promoting an anti-tumor immune response in a subject with a cancer, comprising administering to the subject a therapeutically effective amount of a reversible BTK inhibitor, wherein the subject is receiving or has received a CART cell therapy that specifically targets an antigen associated with or expressed by a plurality of cancer cells.
A method of increasing activation, proliferation, and/or expansion of CART cells in a subject having a cancer, comprising administering to the subject a therapeutically effective amount of a reversible BTK inhibitor, wherein the subject is receiving or has received a CART cell therapy that specifically targets an antigen associated with or expressed by a plurality of cancer cells.
A kit comprising a container comprising a composition comprising a reversible BTK inhibitor, and optionally a pharmaceutically acceptable carrier, and a package insert comprising instructions for administration of the reversible BTK inhibitor for treating or delaying progression of cancer in a subject receiving CART cell therapy.
A kit comprising a medicament comprising a composition comprising a reversible BTK inhibitor, and optionally a pharmaceutically acceptable carrier, and a package insert comprising instructions for administration of the reversible BTK inhibitor for treating or delaying progression of cancer in a subject receiving CART cell therapy.
A kit comprising a container comprising a composition comprising a reversible BTK inhibitor, and optionally a pharmaceutically acceptable carrier, and a package insert comprising instructions for administration of the reversible BTK inhibitor for inducing or promoting an anti-tumor immune response in a subject receiving CART cell therapy.
A kit comprising a medicament comprising a composition comprising a reversible BTK inhibitor, and optionally a pharmaceutically acceptable carrier, and a package insert comprising instructions for administration of the reversible BTK inhibitor for inducing or promoting an anti-tumor immune response in a subject receiving CART cell therapy.
A kit comprising a container comprising a composition comprising a reversible BTK inhibitor, and optionally a pharmaceutically acceptable carrier, and a package insert comprising instructions for administration of the reversible BTK inhibitor for increasing activation, proliferation, and/or expansion of CART cells in a subject receiving CART cell therapy.
A kit comprising a medicament comprising a composition comprising a reversible BTK inhibitor, and optionally a pharmaceutically acceptable carrier, and a package insert comprising instructions for administration of the reversible BTK inhibitor for increasing activation, proliferation, and/or expansion of CART cells in a subject receiving CART cell therapy.
Use of a reversible BTK inhibitor for treating or delaying progression of a cancer in a subject receiving or that has received a CART cell therapy.
Use of a reversible BTK inhibitor in the manufacture of a medicament for treating or delaying progression of a cancer in a subject receiving or that has received a CART cell therapy.
Use of a reversible BTK inhibitor for inducing or promoting an anti-tumor immune response in a subject receiving or that has received a CART cell therapy.
Use of a reversible BTK inhibitor in the manufacture of a medicament for inducing or promoting an anti-tumor immune response in a subject receiving or that has received a CART cell therapy.
Use of a reversible BTK inhibitor for increasing activation, proliferation, and/or expansion of CART cells in a subject receiving or has received a CART cell therapy.
Use of a reversible BTK inhibitor in the manufacture of a medicament for increasing activation, proliferation, and/or expansion of CART cells in a subject receiving or has received a CART cell therapy.
Dependencies are inferred from the claim text.